Market Research Logo

Global Antiemetic Drug Market 2017-2021

Global Antiemetic Drug Market 2017-2021

About Antiemetic Drug

Emesis is defined as forceful expulsion of stomach content either due to humoral stimulation due to chemoreceptor trigger zone (CRTZ) or neural stimulation of emetic centers. The various drugs that are used to treat this condition of emesis are known as antiemetics. The various classes of drug available for management of emesis are serotonin antagonist, dopamine antagonist, NK1 receptor antagonist, antihistaminic, steroids, and anticholinergic. The various applications of antiemetic drugs include chemotherapy, surgery, gastroenteritis, morning sickness, motion sickness, stress-induced emesis, and drugs-induced emesis. This market is primarily volume driven as majority of drugs are available in generic form.

Technavio’s analysts forecast the global antiemetic drug market to grow at a CAGR of 6.13% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global antiemetic drug market for 2017-2021. To calculate the market size, the report considers the sales from branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Antiemetic Drug Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Johnson & Johnson
  • Pfizer
  • Sanofi
Other prominent vendors
  • Abbott
  • Bristol-Myers Squibb
  • Cipla
  • Eisai
  • Eli Lilly
  • Glenmark
  • Helsinn Healthcare
  • Heron Therapeutics
  • IPCA Laboratories
  • Lupin
  • Merck
  • Novartis
  • RedHill
  • Sun Pharmaceutical Industries
  • Takeda Pharmaceutical
Market driver
  • Increased prevalence of cancer
  • For a full, detailed list, view our report
Market challenge
  • Lack of animal models
  • For a full, detailed list, view our report
Market trend
  • Inorganic growth strategies
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Antiemetic Drug Market 2017-2021

Technavio recognizes the following companies as the key players in the global antiemetic drug market: GlaxoSmithKline, Johnson & Johnson, Pfizer, and Sanofi.

Other Prominent Vendors in the market are: bbott, Bristol-Myers Squibb, Cipla, Eisai, Eli Lilly, Glenmark, Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin, Merck, Novartis, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is inorganic growth strategies. The inorganic growth strategies are expected to contribute the growth of antiemetic drug market. These inorganic growth strategies include global M&A, partnerships, and regional acquisition. Owing to these inorganic growth strategies, the market penetration of vendors is improved, technological advancement due to mutual collaboration in R&D, and improved the product portfolio.”

According to the report, one of the major drivers for this market is increased prevalence of cancer. With this ever-increasing population of cancer patients, effective therapies are necessary to save lives and improve their quality of life. Chemotherapy is widely used therapy to help individuals fight cancer. The data estimated that around 3.8-4.2 million cancer patients undergo chemotherapy treatment every year. However, chemotherapy is associated with many side effects. The majority of chemotherapeutic agents cause serious nausea and vomiting with its treatment. This is termed as CINV. The data also reported that around eight out 10 patients undergoing chemotherapy encounter CINV as a debilitating side effect. It is one of the major factors for premature discontinuation of chemotherapy.

Further, the report states that one of the major factors hindering the growth of this market is lack of animal models. Nausea and vomiting are most common symptoms associated either as a symptom of a disease or the side effect of a various class of drugs. The development of newer antiemetic drugs and analyzing emetic liability in novel chemical entities mainly rely on the models that mimic the complexity of these multi-system reflexes. Animal models in preclinical studies are widely used for examining the safety, efficacy, and toxicity of molecule under examination before evaluating it on human volunteers.



Companies Mentioned

GlaxoSmithKline, Johnson & Johnson, Pfizer, Sanofi, bbott, Bristol-Myers Squibb, Cipla, Eisai, Eli Lilly, Glenmark, Helsinn Healthcare, Heron Therapeutics, IPCA Laboratories, Lupin, Merck, Novartis, RedHill, Sun Pharmaceutical Industries, and Takeda Pharmaceutical.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Table Application of antiemetic drugs
    • Table Major antiemetic drug class
    • Table Global antiemetic drugs market snapshot 2016
  • An overview of emesis
    • Table Steps involved in emesis
    • Table Mechanism of emesis
    • Table Causes of emesis
  • Market landscape
    • Market overview
      • Table Global antiemetic drug market snapshot
      • Table Global antiemetic drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis in global antiemetic drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline analysis of vendors in Phase I
    • Table Pipeline analysis of vendors in Phase II
    • Table Pipeline analysis of vendors in Phase III
    • Table Key clinical trials
  • Market segmentation by application
    • Table Market segmentation by application 2016
    • Chemotherapy
      • Table Global antiemetic chemotherapeutic drugs market 2016-2021 ($ millions)
    • Surgery
      • Table Global antiemetic surgery treatment market 2016-2021 ($ millions)
    • Gastroenteritis
      • Table Global antiemetic gastroenteritis drugs market 2016-2021 ($ millions)
    • Others
      • Table Various emetics symptoms
      • Table Global antiemetic other drugs market 2016-2021 ($ millions)
  • Market segmentation by drug class
    • Table Segmentation of global antiemetic drugs market by drug class 2016
    • 5-Hydroxytryptamine 3 (5-HT 3) receptor antagonist
    • Dopamine antagonist
    • Neurokinin-1 (NK 1) receptor antagonist
    • Cannabinoid receptor antagonist
    • Others
      • Table Other drug classes of antiemetic drugs market
  • Geographical segmentation
    • Table Segmentation of global antiemetic drugs market by geography 2016 and 2021
    • Table Segmentation of global antiemetic drugs market revenue by geography 2016-2021
    • Antiemetic drug market in Americas
      • Table Market scenario in Americas
      • Table Antiemetic drugs market in Americas 2016-2021 ($ millions)
    • Antiemetic drug market in EMEA
      • Table Market scenario in EMEA
      • Table Antiemetic drugs market in EMEA 2016-2021 ($ millions)
    • Antiemetic drug market in APAC
      • Table Market scenario in APAC
      • Table Antiemetic drugs market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Factors causing PONV
      • Table Triggers and therapeutics for CINV
    • Market challenges
      • Table Revenue of Kytril marketed by F. Hoffmann-La Roche 2014-2016 ($ millions)
  • Market trends
    • Inorganic growth strategies
    • Guidelines for CINV drug development
    • Antiemetic oral soluble films
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global antiemetic drug market 2016
      • Table Competitive factors of global antiemetic drugs market
      • Table Market penetration of various global antiemetic drugs manufacturers 2016
      • Table Strategic success factors of companies in global antiemetic drugs market
  • Key vendor analysis
    • GlaxoSmithKline
      • Table GSK: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Johnson & Johnson
      • Table Johnson & Johnson: Key highlights
      • Table Johnson & Johnson: Strength assessment
      • Table Johnson & Johnson: Strategy assessment
      • Table Johnson & Johnson: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report